Olfactory and Gustatory Dysfunction in a COVID 19 Patient with Ankylosing Spondylitis Treated with Etanercept: Case Report
The neurologic manifestations concerning coronavirus disease 2019 (COVID 19) are highly penetrated. Anosmia and ageusia are one of the common acute neurologic symptoms, which develop in the early stage of COVID 19. However, it is not reported that how immunosuppressive agents affect these symptoms. We report olfactory and gustatory dysfunctions in a patient with ankylosing spondylitis (AS) treated with etanercept during COVID 19. A 53 year old female showing AS controlled with tumor necrosis factor a inhibitor, etanercept, had been diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) infection, presenting cough and rhinorrhea. One month after diagnosis, she complained about hyposmia and hypogeusia two days before the seronegative conversion of SARS CoV 2, which were confirmed by a neurological examination. We speculate that the etanercept may have delayed the development of olfactory and gustatory dysfunction in the patient.
Journal of Korean medical science